Reading the presentation, I was reminded of the Arrowhead Research concerning homing peptides:
http://www.arrowheadresearch.com/technology/homing-peptides
Delivery of canonical (and especially certain classes of non-canonical) siRNA is a very big business.
This could be an "market disruptive" development that PYC could exploit.
Silencing siRNA (over a protein class) could lead the way for targetted therapeutics for Phylomers (silencing over a protein "phase").
Hence there is potential for PYC to participate in markets around siRNA delivery - which is currently a very lucrative place to be.
boston tides presentation, page-5
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $466.6M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.8¢ | $519.2K | 5.169M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 182466 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 101115 | 2 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |